Contents
pdf Download PDF pdf Download XML
97 Views
29 Downloads
Share this article
Research Article | Volume 16 Issue 2 (None, 2023) | Pages 29 - 31
Rapid clearance of erythrodermic psoriasis with apremilast
 ,
 ,
 ,
 ,
Under a Creative Commons license
Open Access
PMID : PMC5776028
Received
May 19, 2017
Published
Dec. 1, 2017
Abstract

Background:Apremilast is a new immunomodulatory drug, a small molecule inhibitor of PDE4, which down-regulates the expression of multiple pro-inflammatory cytokines, such as tumor necrosis factor alpha, interleukin 17, interleukin 23. Main observations:We describe a case of a 54-year-old man with erythroderma in the course of psoriasis (PASI=49), with contraindications to other psoriasis therapies, in whom total clearance of skin lesions was achieved by day 20 after therapy with apremilast at a dose of 30 mg bid (ΔPASI = 100). The patient had a history of prior use of cyclosporine, methotrexate and adalimumab. His comorbidities included obesity, fatty liver and hypercholesterolemia.Conclusion:In this case of erythroderma in the course of psoriasis apremilast led to total clearance of all cutaneous lesions.

Keywords
Recommended Articles
Case Report
Concurrent Lepra Reactions; Type 1 and Type 2 in a young male patient with borderline leprosy: Clinical and Histopathological correlation
...
Published: 02/09/2025
Original Article
Comparative Evaluation of Intralesional Corticosteroid Injection and Surgical Excision in Hypertrophic Scar Treatment
...
Published: 04/06/2022
Research Article
Efficacy of supra bioavailable itraconazole and conventional itraconazole at different dosing regimens in glabrous tinea infection
Published: 02/02/2024
Research Article
Multiple eruptive periungual pyogenic granulomas during anti-CD20 monoclonal antibody therapy for rheumatoid arthritis
Published: 19/12/2010
© Copyright Spejalisci Dermatolodzy